Trial Profile
A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms FIL-FOLL12
- 12 Dec 2023 Results(n=343) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 16 Jun 2022 Status changed from active, no longer recruiting to completed.